Reading STOK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track STOK free→Reading STOK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track STOK free→QuarterlyIQ Insights · STOK
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 7, 2026, Stoke Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter end March 31, 2026.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (d) On April 3, 2026, the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (“Stoke” or the “Company”), increased the size of the Board to ten (10) directors and, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed G. Clare Kahn, Ph.D. to serve on the Board as a Class I director, effec…
Changes in Registrant’s Certifying Accountants. (a) Dismissal of Previous Independent Registered Public Accounting Firm On March 23, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Stoke Therapeutics, Inc. (the “Company”) dismissed KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm. The reports of KPMG on the consolidated financial statements of the Company as of and for the fiscal years ended December 31, 2025 and 2024 did not cont…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 13, 2026, the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (the “Company”) approved a discretionary bonus of $697,125 for Ian F. Smith, the Company’s Chief Executive Officer (the “Bonus”). Mr. Smith did not participate in the Company’s 2025 annual bonus program. The determination to grant Mr. Smith the Bonus was based up…
by reference. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STOKE THERAPEUTICS, INC. Date: January 27, 2026 By: /s/ Thomas E. Leggett Thomas E. Leggett Chief Financial Officer
Entry into a Material Definitive Agreement. On January 21, 2026, Stoke Therapeutics, Inc. (the “Company”) entered into a new lease for its corporate headquarters and laboratory with NWALP PHOP Property Owner LLC, located at 245 Fifth Avenue, Waltham, Massachusetts (the “Lease Agreement”), in order to expand its office and laboratory space. The Lease Agreement premises include approximately 98,500 square feet. The Lease Agreement will expire on March 31, 2038, and includes two options to furth…
Results of Operations and Financial Condition. On January 11, 2026, Stoke Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing updates to timelines for the completion of enrollment and Phase 3 data readout from its ongoing EMPEROR study and that the Company expects to report that it had approximately $391.7 million in cash, cash equivalents and marketable securities as of December 31, 2025, which, when combined with eligible proceeds from the Biogen colla…
Other Events. The Press Release provides an update related to the design of the Company’s Phase 3 clinical trial of zorevunersen, including the following: Phase 3 Study of Zorevunersen • The Company expects to complete enrollment of 150 patients in the second quarter of 2026, with a data readout in mid-2027 that is anticipated to support the submission of a New Drug Application (an “NDA”) to the U.S. Food and Drug Administration (the “FDA”). The Company plans to initiate a rolling NDA submiss…
Results of Operations and Financial Condition. On November 4, 2025, Stoke Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Executive Officer Appointment On October 5, 2025, the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (the “Company”) appointed Ian F. Smith, who has been serving as the Company’s Interim Chief Executive Officer since March 19, 2025, as the Company’s permanent Chief Executive Officer and principal executive officer (the “Smith Ap…
Results of Operations and Financial Condition. On August 12, 2025, Stoke Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025, and providing business updates, including new data from its ongoing open label extension (“OLE”) studies of zorevunersen extending out to three years and the initiation of the Phase 1 clinical study of STK-002 in patients with Autosomal Dominant Optic Atrophy (ADOA). A copy of the press release…
Results of Operations and Financial Condition. On May 13, 2025, Stoke Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this report.
Departure of Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 16, 2025, Dr. Edward Kaye, M.D., 75, the Company’s Chief Executive Officer (“CEO”) and a director, informed the Company’s Board of Directors (the “Board”) of his intention to step down from his position as the Company’s CEO, effective March 19, 2025 (the “Transition Date”). Dr. Kaye will continue to serve as an advisor and a non-executive member of the Board following the Tr…
Results of Operations and Financial Condition. On March 18, 2025, Stoke Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this report.
Entry into a Material Definitive Agreement. On February 14, 2025, Stoke Therapeutics, Inc., a Delaware corporation (the “Company”) entered into a License and Collaboration Agreement (the “Agreement”) with Biogen International GmbH (“Biogen”) for the development and commercialization of zorevunersen (STK-001) and other potential products directed to SCN1A (Dravet syndrome). Pursuant to the Agreement, the Company granted to Biogen an exclusive, royalty-bearing, sublicensable and transferable li…
Other Events. The Company also reported that its cash, cash equivalents, and marketable securities, together with the upfront payment and other eligible cash flows payable by Biogen pursuant to the Agreement, are expected to fund operations through to mid-2028. The Company plans to initiate the Phase 3 Emperor study in the second quarter of 2025, and data are anticipated in the second half of 2027, pending enrollment and study timelines. Forward-Looking Statements This Current Report on Form…
Importance-ranked changes since the prior daily snapshot.
Confidence changed from 'medium' to 'high'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.